Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Rhea-AI Summary
Aclarion (Nasdaq: ACON) released a new physician video (April 7, 2026) featuring Mr. John Sutcliffe of The London Spine Clinic demonstrating real-world use of Nociscan to evaluate chronic low back pain.
Nearly 100 Nociscans have been performed at The London Clinic; Nociscan uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers linked to disc pain. According to the company, clinical data showed up to 97% surgical success when all Nociscan-positive discs are treated, and the video signals growing physician adoption at a leading international center.
Positive
- Nearly 100 Nociscans performed at The London Clinic
- Up to 97% surgical success when all Nociscan-positive discs are treated
- Non-invasive MR spectroscopy biomarker approach for disc pain differentiation
- Physician endorsement from Lead Clinician John Sutcliffe supports clinical utility
Negative
- Adoption concentrated at a single center: ~100 scans at The London Clinic
- No financial or commercialization metrics provided to assess market impact
News Market Reaction – ACONW
In the Apr 7 session, ACONW gained 20.18%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Rights plan adoption | Positive | +0.3% | Adoption of one-year limited duration stockholder rights plan by the Board. |
| Mar 19 | CEO strategy letter | Positive | +0.3% | CEO letter outlining 2026 priorities, Nociscan adoption, and cash runway into 2028. |
| Mar 17 | ROTH conference | Positive | +28.7% | Participation in 38th Annual ROTH Conference to discuss Nociscan and balance sheet. |
| Mar 12 | LSI conference attendance | Positive | +8.1% | CEO attendance at LSI USA 2026 to meet investors and partners about Nociscan. |
| Feb 5 | Chairman letter | Positive | +3.1% | Shareholder letter detailing CLARITY trial plans, cash runway, and capital actions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Aclarion news has generally coincided with modest positive price reactions, especially around conferences and strategic updates.
Over recent months, Aclarion highlighted shareholder communications, conferences, and strategic plans. A Mar 19, 2026 rights plan and CEO letter emphasized long-term value, Nociscan adoption, and a cash runway into 2028. Earlier in March, ROTH and LSI conference participation focused on expanding Nociscan in the UK and US and showcasing a strong balance sheet. A Feb 5, 2026 chairman’s letter detailed the 300-patient CLARITY trial and capital structure cleanup. Today’s adoption update at The London Clinic fits this commercialization narrative.
Key Terms
biomarkers medical
augmented intelligence technical
mr spectroscopy medical
chemical biomarkers medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice
- Nearly 100 Nociscans performed at The London Clinic, reflecting increasing utilization for evaluation of chronic low back pain
BROOMFIELD, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, one of the United Kingdom’s leading private hospitals. The video is available here.
With more than 30 years of experience in treating patients with all types of spinal conditions, including back and neck pain, Mr. Sutcliffe also serves as the Lead Clinician at The London Spine Clinic and is frequently referred complex spinal cases for assessment and treatment. The video highlights his experience using Nociscan to evaluate patients with chronic low back pain.
“Nociscan provides an additional layer of insight that complements traditional imaging,” said Mr. Sutcliffe. “Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain.”
To date, nearly 100 Nociscans have been conducted at The London Clinic. Nociscan is a non-invasive solution that helps physicians differentiate between painful and non-painful discs in the lumbar spine by leveraging MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain. The continued use of Nociscan at The London Clinic reflects sustained physician engagement and growing integration of Nociscan into routine clinical practice.
“This video offers a compelling perspective on how Nociscan is being used in day-to-day clinical practice,” said Brent Ness, Chief Executive Officer of Aclarion. “Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain.”
Chronic low back pain is a significant global healthcare challenge, affecting approximately 266 million people worldwide. When used alongside other diagnostic tools, clinical data has demonstrated up to a
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding Aclarion Highlights Growing Adoption of Nociscan at The London Clinic, and the potential benefits of our Nociscan technology. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
